Faropenem, a highly efficacious and orally bioavailable beta-lactam antibiotic, exhibits an extensive range of in vitro antimicrobial activity against diverse gram-positive and -negative aerobes and anaerobes. Notably, Faropenem possesses inherent resistance to hydrolysis by virtually all beta-lactamases, including extended-spectrum beta-lactamases and AmpC beta-lactamases. Moreover, Faropenem has been developed as an oral prodrug, namely faropenem medoxomil, for the investigation of respiratory tract infections.
Isepamicin (Sch 21420) is a potent aminoglycoside antibacterial compound with enhanced efficacy against strains harboring type I 6'-acetyltransferase. Its antibacterial spectrum encompasses Enterobacteriaceae and staphylococci, while exhibiting resistance against anaerobes, Neisseriaceae, and streptococci. Moreover, Isepamicin displays a robust concentration-dependent bactericidal effect, a prolonged post-antibiotic effect lasting several hours, and is capable of inducing adaptive resistance.
Gepotidacin hydrochloride, also known as GSK-2140944 hydrochloride, is a potent Type II DNA topoisomerase inhibitor. Gepotidacin hydrochloride is a novel antibacterial drug candidate. Gepotidacin hydrochloride Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats. Gepotidacin hydrochloride is efficacious in a nonhuman primate model of pneumonic plague. When tested against Gram-negative (n = 333) and Gram-positive (n = 225) anaerobes by agar dilution, Gepotidacin hydrochloride inhibited 90% of isolates at concentrations of 4 and 2 μg mL, respectively.